<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029271</url>
  </required_header>
  <id_info>
    <org_study_id>CIP338</org_study_id>
    <nct_id>NCT05029271</nct_id>
  </id_info>
  <brief_title>InPen User Experience</brief_title>
  <official_title>InPen User Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the user experience of InPen™ with InPen™ Diabetes&#xD;
      Management App and Guardian 4 system in adult patients with type 1 diabetes for the design of&#xD;
      a future pivotal study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, single arm study in insulin-requiring adult subjects with type&#xD;
      1 diabetes treated with MDI (basal and bolus) therapy.&#xD;
&#xD;
      The total study duration will be approximately 10 weeks long for each participant.&#xD;
&#xD;
      The study consists of a run-in (phase 1) and study phases 2, 3 and 4.&#xD;
&#xD;
      Phase 1:&#xD;
&#xD;
      The purpose of the run-in phase is to collect baseline HbA1c and blinded Continuous Glucose&#xD;
      Monitoring (CGM) data while subjects are on their current MDI therapy.&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
      All subjects will utilize a smart bolus insulin pen injector (InPen™) and app with dose&#xD;
      calculator (InPen™ Diabetes Management App), and will continue their own SMBG, iscCGM or&#xD;
      RT-CGM for two weeks.&#xD;
&#xD;
      Phase 3:&#xD;
&#xD;
      Subjects will continue on the InPen and InPen App for another two weeks utilizing the HCP&#xD;
      insights gained during the titration follow-up visit.&#xD;
&#xD;
      Phase 4:&#xD;
&#xD;
      All subjects will utilize the InPen™ system consisting of:&#xD;
&#xD;
        -  InPen™ and InPen™ Diabetes Management App&#xD;
&#xD;
        -  Guardian™ 4 system (RT-CGM)&#xD;
&#xD;
        -  Guardian™ 4 sensor&#xD;
&#xD;
        -  Guardian™ 4 transmitter&#xD;
&#xD;
        -  Guardian™ 4 app&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Arm exploratory and descriptive study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endpoints are exploratory and descriptive related to time in glycemic range.</measure>
    <time_frame>Above endpoints will be categorized by daytime and night-time and overall (24hour).</time_frame>
    <description>Percentage of Time spent within range with sensor glucose (SG) between 70-180 mg/dL (3.9-10.0 mmol/L)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Type 1</condition>
  <arm_group>
    <arm_group_label>InPen with Guardian 4 System Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will move from phase 1 to phase 4 of the study.&#xD;
Phase 1:&#xD;
Blinded Continuous Glucose Monitoring (CGM) will be utilized while subjects are on their current MDI therapy.&#xD;
Phase 2:&#xD;
All subjects will utilize a smart bolus insulin pen injector (InPen™) and app with dose calculator (InPen™ Diabetes Management App).&#xD;
Phase 3:&#xD;
Subjects will continue on the InPen and InPen App utilizing the HCP insights gained during the titration follow-up visit.&#xD;
Phase 4:&#xD;
All subjects will utilize the InPen™ with the Guardian™ 4 system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InPen with Guardian 4 System</intervention_name>
    <description>Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.</description>
    <arm_group_label>InPen with Guardian 4 System Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is aged 18-75 years at time of screening&#xD;
&#xD;
          2. Subject is on MDI therapy (defined as ≥ 3 insulin injections per day and on a&#xD;
             basal/bolus regimen) ≥1 year prior to screening&#xD;
&#xD;
          3. Subject has a clinical diagnosis of type 1 diabetes for 1 year prior to screening&#xD;
&#xD;
          4. Subject has a Glycosylated hemoglobin (HbA1c) less than 10% as assessed by local lab&#xD;
             &lt;15 days prior to screening or at time of screening visit&#xD;
&#xD;
          5. Subject is on MDI therapy with&#xD;
&#xD;
               1. SMBG,&#xD;
&#xD;
               2. Continuous Glucose Monitoring (CGM), or&#xD;
&#xD;
               3. Intermittent Scanning CGM (iscCGM)&#xD;
&#xD;
          6. Subject is willing to upload data from a BG meter, must have internet access and a&#xD;
             compatible computer system that meets the requirements for uploading data at home.&#xD;
&#xD;
          7. Subject is willing and able to sign and date informed consent, comply with all study&#xD;
             procedures, and wear all study devices, as required during the study.&#xD;
&#xD;
          8. Subject is willing to take or switch to one of the following insulins:&#xD;
&#xD;
               1. Humalog™* (insulin lispro injection)&#xD;
&#xD;
               2. NovoLog™* (insulin aspart)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of child-bearing potential who have a positive pregnancy test at screening or&#xD;
             plan to become pregnant during the course of the study.&#xD;
&#xD;
          2. Women who are breastfeeding.&#xD;
&#xD;
          3. Subject has any unresolved adverse skin conditions in the area of sensor placement&#xD;
             (e.g. psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).&#xD;
&#xD;
          4. Subject is actively participating in an investigational study (drug or device) wherein&#xD;
             he/she has received treatment from an investigational study drug or device in the last&#xD;
             2 weeks before enrollment into this study, as per investigator judgment.&#xD;
&#xD;
          5. Subject is currently abusing illicit drugs, marijuana, alcohol or prescription drugs&#xD;
             (other than nicotine), per investigator judgment.&#xD;
&#xD;
          6. Subject has any other disease or condition that may preclude the patient from&#xD;
             participating in the study, per investigator judgment.&#xD;
&#xD;
          7. Subject is legally incompetent, illiterate or vulnerable person.&#xD;
&#xD;
          8. Research staff involved with executing the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabiona Hoevelaken</last_name>
    <phone>+31 (0)6 115 978 31</phone>
    <email>fabiona.hoevelaken@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roseline Re</last_name>
    <phone>+33 (0)6 845 204 25</phone>
    <email>roseline.re@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabeter</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Henk-Jan Aanstoot, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Henk-Jan Aanstoot, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Johan Jendle, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Johan Jendle, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Daily injections</keyword>
  <keyword>Continuous Glucose Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

